Shares of PROLOR Biotech, Inc. (PBTH) have been on the move since we told readers about the company in January and jumped another 5.2% this past week. The biopharmaceutical company which utilizes patented technology to develop longer-acting, proprietary versions of already approved therapeutic proteins led gains on the Bloomberg Israel-U.S. Index in January with a 45 percent surge after dropping 34 percent last year. Just days after we told our premium subscribers that we were hearing positive clinical data chatter from various analysts and others at healthcare conferences in San Francisco, the company announced positive top-line results from their pilot study of their Long-Acting Human Growth Hormone Injected Twice Per Month. Dr. Avri Havron, Chief Executive Officer of PROLOR was very encouraged by the findings and hinted that hGH-CTP can potentially provide a safe and effective new therapeutic option for adults with growth hormone deficiency when injected once-weekly, versus the daily injections of conventional hGH that are currently required.
